PTC Therapeutics, Inc. (PTCT)
PTCT Stock Price Chart
Explore PTC Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PTCT price movements and trends.
PTCT Company Profile
Discover essential business fundamentals and corporate details for PTC Therapeutics, Inc. (PTCT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jun 2013
Employees
939.00
Website
https://www.ptcbio.comCEO
Matthew B. Klein F.A.C.S.,
Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
PTCT Financial Timeline
Browse a chronological timeline of PTC Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.11, while revenue estimate is $187.58M.
Earnings released on 7 Aug 2025
EPS came in at -$0.83 surpassing the estimated -$1.07 by +22.43%, while revenue for the quarter reached $178.88M , missing expectations by -6.57%.
Earnings released on 6 May 2025
EPS came in at $10.04 surpassing the estimated -$1.08 by +1.03K%, while revenue for the quarter reached $1.18B , beating expectations by +215.64%.
Earnings released on 27 Feb 2025
EPS came in at -$0.24 surpassing the estimated -$1.12 by +78.57%, while revenue for the quarter reached $213.17M , missing expectations by -14.39%.
Earnings released on 7 Nov 2024
EPS came in at -$1.39 surpassing the estimated -$1.54 by +9.74%, while revenue for the quarter reached $196.79M , beating expectations by +3.31%.
Earnings released on 8 Aug 2024
EPS came in at -$1.16 falling short of the estimated -$1.00 by -16.00%, while revenue for the quarter reached $186.70M , beating expectations by +0.75%.
Earnings released on 25 Apr 2024
EPS came in at -$1.20 surpassing the estimated -$1.21 by +0.83%, while revenue for the quarter reached $210.12M , beating expectations by +23.29%.
Earnings released on 29 Feb 2024
EPS came in at -$0.24 falling short of the estimated $0.29 by -182.76%, while revenue for the quarter reached $307.06M , missing expectations by -4.43%.
Earnings released on 26 Oct 2023
EPS came in at -$1.76 falling short of the estimated -$0.85 by -107.06%, while revenue for the quarter reached $196.58M , missing expectations by -6.48%.
Earnings released on 3 Aug 2023
EPS came in at -$2.66 falling short of the estimated -$1.58 by -68.35%, while revenue for the quarter reached $213.81M , beating expectations by +3.29%.
Earnings released on 27 Apr 2023
EPS came in at -$1.88 falling short of the estimated -$1.64 by -14.63%, while revenue for the quarter reached $220.38M , beating expectations by +7.78%.
Earnings released on 21 Feb 2023
EPS came in at -$2.35 falling short of the estimated -$1.96 by -19.90%, while revenue for the quarter reached $167.41M , missing expectations by -11.13%.
Earnings released on 27 Oct 2022
EPS came in at -$1.53 falling short of the estimated -$1.37 by -11.68%, while revenue for the quarter reached $217.13M , beating expectations by +21.63%.
Earnings released on 4 Aug 2022
EPS came in at -$2.13 falling short of the estimated -$1.67 by -27.54%, while revenue for the quarter reached $165.53M , beating expectations by +2.10%.
Earnings released on 3 May 2022
EPS came in at -$1.78 falling short of the estimated -$1.55 by -14.84%, while revenue for the quarter reached $148.74M , beating expectations by +1.24%.
Earnings released on 22 Feb 2022
EPS came in at -$2.03 falling short of the estimated -$1.79 by -13.41%, while revenue for the quarter reached $165.23M , beating expectations by +9.55%.
Earnings released on 28 Oct 2021
EPS came in at -$1.89 falling short of the estimated -$1.78 by -6.18%, while revenue for the quarter reached $138.74M , beating expectations by +9.73%.
Earnings released on 29 Jul 2021
EPS came in at -$1.68 surpassing the estimated -$1.84 by +8.70%, while revenue for the quarter reached $116.68M , meeting expectations.
Earnings released on 4 May 2021
EPS came in at -$1.83 falling short of the estimated -$1.59 by -15.09%, while revenue for the quarter reached $117.94M , beating expectations by +23.16%.
Earnings released on 25 Feb 2021
EPS came in at -$1.08 falling short of the estimated -$0.90 by -20.00%, while revenue for the quarter reached $118.86M , beating expectations by +6.74%.
Earnings released on 29 Oct 2020
EPS came in at -$1.03 surpassing the estimated -$1.10 by +6.36%, while revenue for the quarter reached $118.40M , beating expectations by +1.62K%.
PTCT Stock Performance
Access detailed PTCT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.